Evidence map›Paper›PMID 42859599›Full record

ArticleHealth science reports2026

Small Molecule Therapeutic Approaches With a Greater Focus on Hearing Loss: A Review.

Maryam Naghinejad, Farzaneh Motallebi, Elaheh Hasani, Moein Kohkalani, Sepideh Parvizpour, Sima Mansoori Derakhshan

Abstract read
In one paragraph

Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam NaghinejadDepartment of Medical Genetics, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0001-9926-7474
Farzaneh MotallebiStudent Research Committee Golestan University of Medical Sciences Gorgan Iran.ORCID https://orcid.org/0009-0006-7228-8826
Elaheh HasaniDepartment of Medical Genetics, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0009-0000-7457-0194
Moein KohkalaniDepartment of Medical Genetics, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0009-0004-8475-0905
Sepideh ParvizpourDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0003-1865-5040
Sima Mansoori DerakhshanDepartment of Medical Genetics, Faculty of Medicine Tabriz University of Medical Sciences Tabriz Iran.ORCID https://orcid.org/0000-0003-3398-941X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Hearing loss (HL) is one of the most common sensory impairments worldwide and has substantial effects on quality of life and daily functioning. Although cochlear implants and hearing aids have markedly improved the management of hearing impairment, these devices do not directly address the underlying pathogenic mechanisms of HL. This review aims to summarize the pathophysiology and classification of HL and to discuss the potential therapeutic applications of small molecules (SMs) in its management. Methods: This review focuses on the major pathological mechanisms involved in different forms of HL and summarizes preclinical and clinically relevant SM-based therapeutic approaches. The reviewed strategies include pharmacological chaperones, transcriptional modulation, ion-channel modulators, neuroprotective compounds, apoptosis inhibitors, and regenerative approaches. Results: SMs possess physicochemical properties that make them suitable for targeting specific molecular pathways involved in HL. Current evidence suggests that SM-based interventions may act through diverse mechanisms, including attenuation of oxidative stress, inflammation, and apoptosis; modulation of ion channels; support of auditory neuron survival and function; and promotion of regenerative signaling. Conclusion: SM-based therapeutic approaches represent promising strategies for addressing the molecular and cellular mechanisms underlying HL. These approaches may provide valuable directions for future research and support the development of targeted therapies for individuals with hearing impairment.

Indexed as

hearing impairmentshearing loss pathophysiologyhearing loss treatmentsmall molecule therapeutics

Identifiers

PMID42859599
PMCPMC13653448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.